大多数寻找医疗服务机构集团战略的人，实际遇到的是面板或合同问题，而这两者的答案完全相反。 对医疗服务机构而言，难点在于结构：已对38,000人承担了下行风险，却缺少定价所需的每期成本数据。因此任何可信答案都必须同时掌握每期成本和 payer mix，而这正是大多数内部分析止步之处，因为两者分属不同系统。
大多数寻找医疗服务机构集团战略的人，实际遇到的是面板或合同问题，而这两者的答案完全相反。 对医疗服务机构而言，难点在于结构：已对38,000人承担了下行风险，却缺少定价所需的每期成本数据。因此任何可信答案都必须同时掌握每期成本和 payer mix，而这正是大多数内部分析止步之处，因为两者分属不同系统。
这一区分并非学术问题。集团战略回答去哪里竞争：保留哪些基于价值的合同和归属人头，买入或卖出哪些面板或设施，资本与风险如何在单元间流动，以及集团中心做了什么来证明其成本。业务单元战略回答如何取胜：在单一合同内管理每期成本、塑造 payer mix、扩大或缩减面板规模、提升特定归属人头下的每提供者贡献。两者都合理，但使用不同证据，产生不同决策。
两者被混淆的原因是症状往往相同。基于价值合同的业绩平平，看起来既可能是一两个面板表现不佳，也可能是合同归属人头彼此无关。检验方法是拆分观察：若各面板表现一致，则问题是单一合同内的每期成本，组合视角找不到答案；若平均值由一个面板支撑另两个，则是组合问题，仅在弱面板内做每期分析无法解决。
集团战略的第二个用途，也是最常被跳过的，是母公司问题——集团中心增加了什么价值。集团中心证明其成本的方式，要么是跨合同分配风险优于各单元自行操作，要么是提供面板单独无法获得的每期成本数据或 payer mix 纪律，要么是设定提供者自己不会设定的每提供者贡献目标。若三者均无，那就是对面板的税收，诚实的战略答案可能是缩减而非重新定位它。
Corporate Strategy & Transformation（目录编号 t5）运行组合算术——按面板的每提供者贡献、已接受风险下的每期成本、每份合同实际承担的间接费用——并给出分配视图。若答案最终是单一合同的竞争问题，它会直接指出并转向更窄的分析，而非用组合语言包装每期成本问题。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 基于价值合同的集团业绩持平，且内部面板走势不一致
✓ 无人能说明集团中心做了什么，是面板靠自身每期成本数据无法做到的
✓ 基于价值合同的风险分配大致按去年比例，而非按每提供者贡献
通常会让情况更糟的做法。 对实际仅有一个面板的提供者做组合审查，结果建议退出即将成为答案的合同。
It is for you if you run or finance a healthcare provider and the group result is flat and the units inside it are not moving together. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务机构. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Sell coordinated care bundles directly to self-insured employers using existing clinic density and ASC capacity.
The leak it closes. Bypasses commercial payer take-rate (estimated 15–20% of premium) and prior-authorization friction, reducing denial leakage on these lives to near zero
The assumption it rests on. At least two of the five largest self-insured employers in the two metros will sign a 3-year direct contract within 18 months — the engine put the probability at 0.7.
| Investment required | $2M over 36 months ($800K Year 1, $700K Year 2, $500K Year 3) |
| Expected return | 6.0–9.0× on $2M investment |
| Revenue, year 1 | $0 incremental (pilot setup and first contract negotiations) |
| Revenue, year 2 | $4–6M incremental (2–3 employer contracts, 4,000–6,000 covered lives) |
| Revenue, year 3 | $12–18M incremental (5 employer contracts, 10,000–15,000 covered lives) |
| Exit criteria | Terminate pilot and redeploy 4 FTEs if fewer than 2 employer contracts signed by Month 18 OR if operating margin on employer channel falls below 6% for two consecutive quarters |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Corporate Strategy & Transformation, one of 29 engagements the platform runs. For 医疗服务机构 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
集团战略决定进入哪些业务以及资本如何在它们之间流动。业务战略决定在其中一个业务内如何取胜。单一市场公司没有值得付费的集团战略问题，它只有竞争问题。一个拥有三个单元和一张资产负债表的集团两者都有，按错误顺序回答是常见失败。
大型公司的组合审查通常为£150k–£500k，历时八至十二周；精品公司和独立顾问做较窄版本收费£40k–£120k。差异几乎完全来自初级数据收集的范围。若你自己的财务系统已能按单元生成贡献和资本，大部分费用只是购买你已持有数字的分析。
作为总结，是；作为决策规则，不是。增长和份额是两个重要变量，也是最容易获得的两个，这就是矩阵持续存在的原因。当一个份额不高的单元正在产生支撑其他所有业务的现金，而矩阵却建议剥离它时，它就会误导。把它用来组织对话，然后根据资本消耗的回报做出决定。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית